IA Trial Radar | ||
|---|---|---|
El ensayo clínico NCT07449039 (POSTPOD) para Diabetes mellitus gestacional en el embarazo está reclutando. Consulte la vista de tarjeta del Radar de Ensayos Clínicos y las herramientas de descubrimiento de IA para conocer todos los detalles. O haga cualquier pregunta aquí. | ||
Un estudio coincide con los criterios de filtro
Vista de tarjeta
Volver a la búsqueda
Universidad de California en Los ÁngelesPostpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial 50 Posparto
Los detalles del ensayo clínico están disponibles principalmente en inglés. ¡Sin embargo, IA Trial Radar puede ayudar! Simplemente haga clic en 'Explicar el estudio' para ver y discutir la información del estudio en el idioma que haya seleccionado.
El ensayo clínico NCT07449039 (POSTPOD) es un estudio intervencionista para Diabetes mellitus gestacional en el embarazo. Su estado actual es: reclutando. El estudio se inició el 28 de septiembre de 2025, con el objetivo de reclutar a 50 participantes. Dirigido por la Universidad de California en Los Ángeles, se espera que finalice el 1 de junio de 2030. Los datos se actualizaron por última vez en ClinicalTrials.gov el 4 de marzo de 2026.
Resumen
This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes.
Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will al...
Mostrar másTítulo oficial
Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial
Condiciones médicas
Diabetes mellitus gestacional en el embarazoOtros ID del estudio
- POSTPOD
- 25-0020
Número del NCT
Inicio del estudio (real)
2025-09-28
Última actualización
2026-03-04
Fecha de finalización (estimada)
2030-06
Inscripción (prevista)
50
Tipo de estudio
Intervencionista
FASE
N/A
Estado general
Reclutando
Objetivo principal
Otros
Método de asignación
N/A
Modelo de intervención
Grupo único
Enmascaramiento
Ninguno (Abierto)
Brazos / Intervenciones
| Grupo de participantes | Intervención/Tratamiento |
|---|---|
OtrosContinuous Glucose Monitor Administration of a Continuous Glucose Monitor within 2 hours after delivery for 24-hour collection of glycemic data. | Continuous Glucose Monistor Continuous glucose monitoring sensor that provides 24/7 detailed glycemic information. Participants will wear for 24 hours and then be instructed to peel off. |
Resultado primario
Resultado secundario
| Medida de resultado | Descripción de la medida | Periodo de tiempo |
|---|---|---|
Clinical Efficacy Associated with CGM use immediately postpartum as compared to the 2 hr Glucose tolerance test | Regression analysis to assess strength and direction of the relationship between postpartum CGM data and 2 hr GTT | 24 hours postpartum and 1-3 months postpartum |
Clinical Efficacy Associated with CGM use immediately postpartum as compared to the HbA1c test postpartum | Regression analysis to assess strength and direction of the relationship between postpartum CGM data and HbA1c | 24 hours postpartum and 1-3 months postpartum |
| Medida de resultado | Descripción de la medida | Periodo de tiempo |
|---|---|---|
Patient satisfaction with CGM use immediately postpartum to evaluate long term risk | Patient satisfaction will be measured via survey response on following statements using 5 point likert scale
* Applying the CGM was painless.
* Applying the CGM was easy.
* Wearing the CGM for 24 hours postpartum was painless.
* Wearing the CGM for 24 hours postpartum was easy.
* Wearing the CGM did not interfere with my activities of daily living.
* Wearing the CGM did not cause any side effects.
* Removing the CGM was painless.
* Removing the CGM was easy.
* If given a choice between the 1-3 month postpartum OGTT and wearing the CGM for 24 hours immediately postpartum, I would choose wearing the CGM. | 1-3 months postpartum after glucose tolerance test, 12-24 months postpartum after A1C blood test |
Asistente de participación
Criterios de elegibilidad
Criterios de edad
Adulto, Adulto mayor
Edad mínima
18 Years
Criterios de sexo
Mujer
- Prenatal care at UCLA Health
- Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
- Confirmed gestational diabetes diagnosis based on 2-step approach
- Maternal age >= 18 years
- Pre-gestational diabetes (T1DM or T2DM)
- Multifetal gestation
- Intra-amniotic infection by clinical criteria
- Postpartum hemorrhage
- Maternal ICU admission
- Known allergy to medical-grade adhesive
- Presence of skin lesions at anticipated CGM application site
- Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
- Metformin use
- Steroid use
- Terbutaline use within 4 hours of delivery
- Cystic fibrosis
- MODY (mature onset of diabetes in the young)
Universidad de California en Los Ángeles341 estudios activos para explorarParte responsable del estudio
Christina S. Han, Investigador principal, Division Director, Maternal-Fetal Medicine, University of California, Los Angeles
Contactos centrales del estudio
Contacto: Rujuta Sathe, 310-794-8893, [email protected]
Contacto: Dana Levin-Lopez, MPH, 310-794-8893, [email protected]
1 Centros del estudio en 1 países
California
University of California, Los Angeles, Los Angeles, California, 90095, United States
Dana Levin-Lopez, MPH, Contacto, 310-794-8893, [email protected]
Reclutando